Literature DB >> 29366479

LncRNA CCND2-AS1 promotes proliferation, migration, and invasion in papillary thyroid carcinoma.

Erjie Xia1, Adheesh Bhandari1, Yanyan Shen1, Xiaofen Zhou1, Namita Sindan2, Jingjing Xiang1, Yaoyao Guan1, Fan Yang3, Ouchen Wang4.   

Abstract

In decades, a lot of long non-coding RNAs (LncRNAs) have been proven to exert influences on tumorigenesis in vitro and in vivo. Many lncRNAs have been reported as effective therapeutic targets and biomarkers in various cancers. However, whether LncRNAs are associated with the progression of PTC remains largely unknown. In this study, we measured the expression of CCND2-AS1 in PTC cell lines by quantitative real-time polymerase chain reaction (qRT-PCR).We found that CCND2-AS1 expression was significantly over-expressed in PTC cell lines compared to normal thyroid epithelial cells. Gain-and loss-of-function experiments were performed to investigate the role of CCND2-AS1 in PTC cells. In vitro experiments, we proved that CCND2-AS1 knockdown in TPC1 significantly suppressed cell proliferation, migration, and invasion, while CCND2-AS1 overexpression in BCPAP had the opposite effects. Meanwhile, we also found that CCND2-AS1 could regulate N-cadherin and Vimentin expression, which may influence invasion and migration. Our findings indicate that the lncRNA CCND2-AS1 is a gene associated with PTC and might become a potential therapeutic target.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CCND2-AS1; LncRNA; PTC

Mesh:

Substances:

Year:  2018        PMID: 29366479     DOI: 10.1016/j.bbrc.2018.01.102

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  LncRNA MCM3AP-AS1 promotes proliferation and invasion through regulating miR-211-5p/SPARC axis in papillary thyroid cancer.

Authors:  Meihua Liang; Jinliang Jia; Lili Chen; Biyue Wei; Qiang Guan; Zhaoming Ding; Jiawei Yu; Rui Pang; Guoqing He
Journal:  Endocrine       Date:  2019-04-27       Impact factor: 3.633

2.  LncRNAs as Potential Therapeutic Targets in Thyroid Cancer.

Authors:  Zeeshan Javed; Faiez Ahmed Shah; Sadegh Rajabi; Qamar Raza; Zaheer Iqbal; Mukhtar Ullah; Touqeer Ahmad; Bahare Salehi; Mehdi Sharifi-Rad; Raffaele Pezzani; Farooq Yaqoob; Haleema Sadia; Marcello Iriti; Javad Sharifi-Rad; William C Cho
Journal:  Asian Pac J Cancer Prev       Date:  2020-02-01

3.  Aberrant methylation-mediated downregulation of lncRNA CCND2 AS1 promotes cell proliferation in cervical cancer.

Authors:  Chengcheng Zhao; Jian Liu; Huazhang Wu; Jiaojiao Hu; Jianquan Chen; Jie Chen; Fengchang Qiao
Journal:  J Biol Res (Thessalon)       Date:  2020-06-26       Impact factor: 1.889

4.  LncRNA GAS8-AS1 suppresses papillary thyroid carcinoma cell growth through the miR-135b-5p/CCND2 axis.

Authors:  NingHeng Chen; DeTao Yin; Bing Lun; XueLi Guo
Journal:  Biosci Rep       Date:  2019-01-11       Impact factor: 3.840

5.  The Long Non-Coding RNA ENST00000489676 Influences Papillary Thyroid Cancer Cell Proliferation and Invasion through Regulating MiR-922.

Authors:  Wenhan Wang; Shujun Xia; Weiwei Zhan
Journal:  J Cancer       Date:  2019-08-29       Impact factor: 4.207

6.  SEC61G regulates breast cancer cell proliferation and metastasis by affecting the Epithelial-Mesenchymal Transition.

Authors:  Lingli Jin; Danxiang Chen; Suzita Hirachan; Adheesh Bhandari; Qidi Huang
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

7.  lncRNA LINC00673 induces proliferation, metastasis and epithelial-mesenchymal transition in thyroid carcinoma via Kruppel-like factor 2.

Authors:  Erjie Xia; Adheesh Bhandari; Yanyan Shen; Xiaofen Zhou; Ouchen Wang
Journal:  Int J Oncol       Date:  2018-08-14       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.